IMRX (Immuneering Corporation) Stock Market Reviews

crown

search

Read and share opinions on IMRX (Immuneering Corporation) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

IMRX

Immuneering Corporation

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
Nov 4, 2025
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX)
Sep 30, 2025
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
Sep 26, 2025
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
Sep 25, 2025
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Sep 24, 2025
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Sep 24, 2025
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
Sep 16, 2025
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
Sep 10, 2025
Immuneering Announces Closing of $25 Million Private Placement
Aug 26, 2025
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
Aug 26, 2025
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
Aug 25, 2025

Reviews